Eprosartan

Eprosartan

Clinical data
Pregnancy category	?
Routes of administration	Oral
ATC code	C09CA02 (WHO) ?
Legal status
Legal status	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Elimination half-life	5 to 9 hours
Excretion	?
Identifiers
IUPAC name 4-[[2-butyl-5-(2-carboxy-3-thiophen-2-yl-prop-1-enyl)- imidazol-1-yl]methyl]benzoic acid
CAS Number	133040-01-4
PubChem CID	9670
DrugBank	APRD00950
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H24N2O4S
Molar mass	Eprosartan mesylate: 520.625 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It is marketed as Teveten® by the Biovail Corporation in the United States and by Solvay Pharmaceuticals elsewhere. It is sometimes paired with hydrochlorothiazide.

The drug acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT₁ receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.

As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.

External links

• Teveten (manufacturer's webdite)
• Eprosartan (patient information)

Template:Angiotensin II receptor antagonists